New Edge Advisors, LLC Altimmune, Inc. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 24,546 shares of ALT stock, worth $190,476. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,546
Previous 22,932
7.04%
Holding current value
$190,476
Previous $152,000
1.32%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ALT
# of Institutions
186Shares Held
39.3MCall Options Held
913KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$41.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$38.7 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$30.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$26.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$21.3 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $380M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...